Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last R$16.20 BRL
Change Today -0.27 / -1.64%
Volume 440.0K
HYPE3 On Other Exchanges
Symbol
Exchange
OTC US
Stuttgart
As of 9:58 AM 09/1/15 All times are local (Market data is delayed by at least 15 minutes).

hypermarcas sa (HYPE3) Snapshot

Open
R$16.05
Previous Close
R$16.47
Day High
R$16.32
Day Low
R$16.05
52 Week High
06/23/15 - R$23.48
52 Week Low
10/27/14 - R$15.31
Market Cap
10.2B
Average Volume 10 Days
2.4M
EPS TTM
R$0.63
Shares Outstanding
632.2M
EX-Date
05/2/13
P/E TM
25.6x
Dividend
--
Dividend Yield
--
Current Stock Chart for HYPERMARCAS SA (HYPE3)

Related News

No related news articles were found.

hypermarcas sa (HYPE3) Related Businessweek News

No Related Businessweek News Found

hypermarcas sa (HYPE3) Details

Hypermarcas S.A., a consumer goods company, engages in the development, production, and sale of drug, health, beauty, and personal care products in Brazil. It operates in two segments, Pharma and Consumption. The company offers sweeteners under the Adocyl, Finn, and Zero-Cal names; and beauty and personal care products, including bleach and hydrogen peroxide, body deodorants, colognes, coloring, deodorants, hair line, hair styling, nail polish, shaving products, skin care, soap, and tanner/sunscreen products. It also provides child care and health products, such as absorbents, adult line, antiseptics, baby bottles, baby lines, baby powder, toothbrushes and dental products, cloth moistened, condoms, baby diapers, dental creams and gels, dental floss and tapes, diaper rash cream, disposable pads, disposable underwear, feminine hygiene products, diapers, intimate hygiene products, kids lines, lubricants, moistened towels, oral antiseptics, oral supplements, palinets, wet wipes, and cottons. In addition, the company offers pharmaceutical products, including over-the-counter medications, such as laxative, antacid, antispasmodic, topical antiseptic, topical, nasal decongestant drugs, and other products; prescription medications under the Farmasa, Neo Química, and Luper names; generic medications; and dermocosmetics. Hypermarcas S.A. was founded in 2001 and is headquartered in São Paulo, Brazil.

12,935 Employees
Last Reported Date: 02/6/15
Founded in 2001

hypermarcas sa (HYPE3) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

hypermarcas sa (HYPE3) Key Developments

Hypermarcas S.A. Presents at Credit Suisse 9th Annual Mid-Summer LatAm Conference, Aug-05-2015

Hypermarcas S.A. Presents at Credit Suisse 9th Annual Mid-Summer LatAm Conference, Aug-05-2015 . Venue: Omni Berkshire Place Hotel, 21 East 52nd Street at Madison Avenue, New York, NY 10022, United States.

Hypermarcas S.A. Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months of 2015; Reports Impairment for the Quarter of 2015

Hypermarcas S.A. announced unaudited consolidated earnings results for the second quarter and six months of 2015. For the quarter, the company reported net revenue BRL 1,256 million, representing a 10.8% growth in the quarter compared to BRL 1,132.7 million, adjusted EBITDA of BRL 297.2 million compared to BRL 287.6 million, net income of BRL 110.9 million or BRL 0.18 per share impacted by the fact of the foreign exchange rate depreciation by about BRL 24 million compared to BRL 122.2 million or BRL 0.19 per share, continuing operations EBIT of BRL 234.6 million compared to BRL 245.2 million for the last year. Operating income before equity income and financial result was BRL 234.596 million compared to BRL 245.191 million, profit before income tax and social contribution was BRL 125.8 million compared to BRL 146.0 million, net income from continuing operations was BRL 112.7 million compared to BRL 126.1 million, net cash provided by operating activities was BRL 59.4 million compared to BRL 185.1 million, acquisitions of property, plant and equipment was BRL 65.2 million compared to BRL 40.0 million and intangible assets was BRL 9.7 million compared to BRL 4.0 million for the last year. For the six months, the company reported net revenue BRL 2,443.3 million compared to BRL 2,191.6 million, adjusted EBITDA of BRL 584.1 million compared to BRL 546.6 million, net income of BRL 201.5 million or BRL 0.32 per share compared to BRL 212.4 million or BRL 0.34 per share, continuing operations EBIT of BRL 464.2 million compared to BRL 463.8 million for the last year. Net debt as on June 2015 was BRL 3,407.4 million. Operating income before equity income and financial result was BRL 464.158 million compared to BRL 436.8 million, profit before income tax and social contribution was BRL 223.2 million compared to BRL 256.7 million, net income from continuing operations was BRL 206.4 million compared to BRL 218.5 million, net cash provided by operating activities was BRL 122.4 million compared to BRL 356.1 million, acquisitions of property, plant and equipment was BRL 106.5 million compared to BRL 95.0 million and intangible assets was BRL 18.0 million compared to BRL 9.3 million for the last year. For the quarter, the company reported impairment of BRL 6.7 million compared to BRL 2.9 million in last year.

Hypermarcas S.A., Q2 2015 Earnings Call, Jul 27, 2015

Hypermarcas S.A., Q2 2015 Earnings Call, Jul 27, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
HYPE3:BZ R$16.20 BRL -0.27

HYPE3 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Bayer AG €116.30 EUR -4.23
GlaxoSmithKline PLC 1,297 GBp -44.00
Pfizer Ltd/India 2,348 INR -12.45
Reckitt Benckiser Group PLC 5,650 GBp -107.00
Sanofi €85.53 EUR -2.64
View Industry Companies
 

Industry Analysis

HYPE3

Industry Average

Valuation HYPE3 Industry Range
Price/Earnings 23.4x
Price/Sales 1.9x
Price/Book 1.2x
Price/Cash Flow 23.8x
TEV/Sales 0.5x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact HYPERMARCAS SA, please visit www.hypermarcas.com.br. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.